WCG's New Seizure eDiary Optimizes Data Collection and Simplifies the Participant Experience
29 Nov 2022
Clinical Study
PRINCETON, N.J. , Nov. 29, 2022 /PRNewswire/ -- WCG, the world's leading provider of solutions that measurably improve the quality and efficiency of clinical research, today launched a new Electronic Seizure Diary (eDiary), which is used to help patients with seizure disorders and their caregivers self-monitor and manage their seizures. WCG is one of two providers selected to develop an eDiary by The Epilepsy Study Consortium.
Designed for both patients and caregivers, and developed by WCG's scientific and neurological experts, the new Seizure eDiary is a user-friendly, screen-based alternative to paper, allowing users to easily log seizures, track medications and appointments, and receive customized content on their condition. The eDiary also provides primary investigators with visibility into a participant's seizure counts when not in clinic. The Seizure eDiary is a key component of WCG's eCOA solution.
"In late phase trials, sponsors need to collect large amounts of data directly from study participants," said Terri Moench, President, WCG Research Solutions. "This new eDiary, delivered via a Bring Your Own Device (BYOD) methodology, improves endpoint-data quality and reduces study participant burden as participants record their information more quickly and accurately. Through this initiative, we're rethinking how technology can be leveraged to advance how we view seizure disorder syndrome tracking and treatment more broadly. We want to progress our understanding of how such a tool can be applied to other rare disease areas to support study participants, caregivers, and their healthcare providers in making more informed healthcare decisions based on real-life situations."
"We're pleased to partner with WCG on this important initiative," said Bree DiVentura, MBA, Executive Director, The Epilepsy Study Consortium. "The development of this eDiary aligns with our mission to help patients manage their condition to live a more productive life. Moreover, it ensures that healthcare providers have the latest data in hand in advance of each study participant's visit, allowing for more effective discussions with participants about what they are experiencing at home."
"Helping patients overcome the challenges of living with epilepsy is an integral part of our mission," continued Jacqueline French, M.D., President of The Epilepsy Study Consortium. "A new seizure eDiary optimized for clinical trials will help us accelerate the development of new therapies in epilepsy and improve patient care. The personal eDiary puts patients and caregivers in control of their information and helps keep an accurate account of seizures."
About WCG
WCG is the world's leading provider of solutions that measurably improve the quality and efficiency of clinical research. Comprised of two divisions, the industry's first central IRB – WCG IRB – and first clinical services organization, WCG enables biopharmaceutical companies, CROs, and institutions to advance the delivery of new treatments and therapies to patients, while maintaining the highest standards of human participant protection. For more information, please visit www.wcgirb.com, www.wcgclinical.com or follow us on Twitter @WCGClinical or LinkedIn.
About the Epilepsy Study Consortium
The Epilepsy Study Consortium (TESC) is a group of scientific investigators from academic medical research centers who are dedicated to accelerating the development of new therapies in epilepsy to improve patient care. The organization's goals include building a partnership between academics, industry and regulatory agencies and optimizing clinical trial methodology in order to responsibly speed new treatments to patients. Visit www.epilepsyconsortium.org to learn more.
For more details,please visit the original website
The content of the article does not represent any opinions of Synapse and its affiliated companies. If there is any copyright infringement or error, please contact us, and we will deal with it within 24 hours.
Organizations
Targets
-Drugs
-Chat with Hiro
Hot reports
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.